Vanda Pharmaceuticals | VNDA - Cost Of Sales


Vanda Pharmaceuticals reported $198.77M in Cost of Sales for its fiscal quarter ending in December of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD 2.52B 2.73B Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 69.29M 19.79M Jun/2026
J&J USD 8.08B 80M Sep/2026
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
Merck USD 3.14B 200M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 93M 862M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.09B 498M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.02B 656M Jun/2026
Takeda JPY 517.6B 42.94B Jun/2026
Teva Pharmaceutical Industries USD 1.98B 30M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 42.19M 3.7M Jun/2026